

IN THE SPECIFICATION

Please amend paragraph 0042 as follows:

Fig. 18(A-B) shows the nucleotide sequence of human MOG gene, SEQ ID NO:9, Genbank accession number Z48051 (Roth et al, submitted (17-Jan-1995) Roth, CNRS UPR 8291, CIGH, CHU Purpan, Toulouse, France, 31300; Gonzalez et al, 1996).

Please amend paragraph 0108 as follows:

Examples of further peptides according to the invention are immunogenic peptides derived from the Nogo protein sequence such as, but not being limited to, the 18-mer p472 Nogo peptide (~~SEQ ID NO:18~~ SEQ ID NO:19) and peptides derived from the Nogo receptor (Fournier et al, 2001) such as the 15-mer peptides of the sequences:

S G V P S N L P Q R L A G R D (SEQ ID NO:28)

T R S H C R L G Q A G S G S S (SEQ ID NO:29)

Please amend paragraph 0119 as follows:

In addition, such compositions may be used to ameliorate the effects of disease that result in a degenerative process, e.g.,⁷ degeneration occurring in either gray or white matter (or both) as a result of various diseases or disorders, including, without limitation: diabetic neuropathy, senile dementias, Alzheimer's disease, Parkinson's

disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), non-arteritic optic neuropathy, intervertebral disc herniation, vitamin deficiency, prion diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral neuropathies associated with various diseases, including but not limited to, uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, IgA- and IgG gamma-pathies, complications of various drugs (e.g., metronidazole) and toxins (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia telangectasia, Friedreich's ataxia, amyloid polyneuropathies, adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's disease, lipoproteinemia, etc.

Please amend paragraph 0144 as follows:

In another embodiment, mononuclear phagocyte cells according to PCT Publication No. WO 97/09985 and U.S. patent application Serial No. ~~09/041,280, filed March 11,~~ 1998, 6,267,955, are injected into the site of injury or lesion within the CNS, either concurrently, prior to, or following parenteral administration of NS-specific activated T cells, an

In re of Appln. No. 09/893,348

NS-specific antigen or peptide derived therefrom or derivative thereof, or a nucleotide sequence encoding such antigen or peptide